Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are characterized by rapid deterioration and a fatal outcome.
Objectives:
Admission triggers, treatment efficacy, and care patterns.
Methods:
Retrospective analysis of patients with PSP/CBD admitted to an inpatient specialized palliative care service.
Results:
In 38 patients, there were 63 admissions for swallowing difficulties, falls, pain, impaired communication, cognitive/mood disturbances, respiratory symptoms, and infection. Mean length of stay was 11.6 days. Treatment response was variable. In 68%, of admission episodes there was stabilization or improvement, 75% were discharged home. In case of readmission, the mean interval has been 9.7 months. Time since diagnosis and admission triggers were not associated with outcome or death.
Conclusion:
Patients showed high symptom load contrasting with discharge rates and subsequent health care utilization. Brief multidisciplinary interventions might be helpful to preserve autonomy.
WilcoxSK. Extending palliative care to patients with Parkinson's disease. Br J Hosp Med (Lond). 2010;71(1):26–30.
2.
FallPASalehAFredricksonMOlssonJEGranerusAK. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord. 2003;18(11):1312–1316.
3.
HawkesCH. Parkinson's disease and aging: same or different process?Mov Disord. 2008;23(1):47–53.
4.
LitvanIMangoneCAMcKeeA. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;60(6):615–620.
5.
WenningGKLitvanIJankovicJ. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998;64(2):184–189.
6.
BensimonGLudolphAAgidYVidailhetMPayanCLeighPN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(pt 1):156–171.
7.
GolbeLIOhman-StricklandPA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130(pt 6):1552–1565.
8.
LudolphACKassubekJLandwehrmeyerBG. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16(3):297–309.
9.
SteeleJCRichardsonJCOlszewskiJ. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333–359.
10.
Dell’aquilaCZoccolellaSCardinaliV. Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism Relat Disord. 2013;19(11):980–985.
SchragABen-ShlomoYQuinnNP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354(9192):1771–1775.
13.
PapapetropoulosSSingerCMcCorquodaleDGonzalezJMashDC. Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord. 2005;11(7):459–463.
14.
National Health Service Evidence, Clinical knowledge summaries, Parkinson’s disease—national clinical guideline for diagnosis and management in primary and secondary care. Web site: www.nice.org.uk/CG035. Published May 28, 2006. last accessed December 16, 2014; anticipated update October 2016.
15.
DuffKGersteneckerALitvanI. Functional impairment in progressive supranuclear palsy. Neurology. 2013;80(4):380–384.
16.
HenslerMPaulSAbrightCLorenzlS. Progressive supranuclear palsy: living environment of the patients [in Germany]. Nervenarzt. 2011;82(2):207–214.
17.
MullerJWenningGKVernyM. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol. 2001;58(2):259–264.
18.
SchragASheikhSQuinnNP. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25(8):1077–1081.
19.
HigginsonIJGaoWSaleemTZ. Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One. 2012;7(11):e46327.
20.
SjostromACHolmbergBStrangP. Parkinson-plus patients—an unknown group with severe symptoms. J Neurosci Nurs. 2002;34(6):314–319.
21.
JaarsmaTBeattieJMRyderM. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11(5):433–443.
22.
FerrisFDBrueraEChernyN. Palliative cancer care a decade later: accomplishments, the need, next steps—from the American Society of Clinical Oncology. J Clin Oncol. 2009;27(18):3052–3058.
23.
QuillTEAbernethyAP. Generalist plus specialist palliative care—creating a more sustainable model. N Engl J Med. 2013;368(13):1173–1175.
